Calypso Medical Names Edward Vertatschitsch President and Chief Executive Officer

SEATTLE--(BUSINESS WIRE)-- Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumors, today announced that it has named Edward Vertatschitsch, Ph.D., president and chief executive officer. Dr. Vertatschitsch first joined Calypso Medical in 2003 and served as the Company’s interim CEO since July 2010.

“Dr. Vertatschitsch has made significant contributions to the development of Calypso Medical’s technology and is the ideal person to lead our company,” said John Freund, M.D., chairman of the board of directors of Calypso Medical and managing director at Skyline Ventures. “As interim chief executive officer, Dr. Vertatschitsch provided strong leadership, helping advance the Calypso® System through global expansion and key partnerships. He has the passion, leadership skills, organizational abilities, intimate knowledge of the technology and unwavering commitment to our customers that are critical to ensuring Calypso Medical’s continued success.”

Dr. Vertatschitsch joined Calypso Medical in 2003 and most recently served as executive vice president of operations and R&D before becoming CEO. Prior to joining Calypso Medical, Dr. Vertatschitsch managed hardware development at Palm Incorporated, where he managed the development of seven successful Palm Personal Digital Assistant (PDA) products, a groundbreaking consumer technology at the time. Earlier in his career, Dr. Vertatschitsch was chief scientist at the Boeing Company where he led the Phased Array Systems Organization. Dr. Vertatschitsch holds a Bachelor of Science degree in physics and a Ph.D. in electrical engineering from McMaster University in Ontario, Canada and has been granted numerous patents.

“Calypso Medical is an outstanding company dedicated to shaping the future of cancer care by providing the precision guidance necessary to improve radiation therapy targeting and delivery. More than 100 leading medical centers around the world have adopted Calypso’s revolutionary GPS for the Body® technology as a standard of care,” said Dr. Vertatschitsch. “As I take on my new role, I look forward to continuing our work with world-class clinicians to expand the global reach of the Calypso System so that cancer patients around the world can benefit from the accurate and precise delivery of radiation.”

About Calypso Medical

Calypso Medical Technologies, Inc. is a Seattle-based, privately held medical device company. The Company’s proprietary tumor localization system utilizes miniaturized implanted devices (Beacon electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products have received U.S. FDA 510(k) clearance and the European Union CE mark for use in the prostate and post-operative prostatic bed. The Calypso System is the only commercially available real-time tracking system for radiation therapy shown to improve patient outcomes for prostate cancer. The Company has strategic relationships with Varian Medical Systems, Siemens Healthcare, Elekta Corporation and Philips Medical. Additional information can be found at www.calypsomedical.com.



CONTACT:

Schwartz Communications
Wendy Mejia / Mollie Warshaw
781-684-0770
[email protected]
or
Calypso Medical
David Betz, 206-330-2621
[email protected]

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Seniors  Women  Technology  Software  Health  Biotechnology  Hospitals  Medical Devices  Oncology  Radiology  Consumer  Men

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.